Related Experiment Video
Updated: May 6, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation
Nancy M Allen LaPointe1, Yuliya Lokhnygina, Gillian D Sanders
1Duke Clinical Research Institute, Durham, NC.
Insights
Many antiarrhythmic drug (AAD) uses in atrial fibrillation (AF) patients with heart failure or coronary artery disease (CAD) did not follow guideline recommendations. This suggests a need for better clinician education on safe AAD prescribing.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Guideline recommendations for antiarrhythmic drugs (AADs) in atrial fibrillation (AF) consider patient comorbidities.
- The clinical implementation of these AAD guidelines is not well understood.
Purpose of the Study:
- To assess the adherence to AAD guideline recommendations in AF patients with specific heart conditions.
- To identify potential gaps in the clinical practice of AF management.
Main Methods:
- A large cohort of AF patients (n=331,274) aged <65 years was identified using commercial health claims data (2006-2010).
- Patients were categorized by the most severe concurrent heart disease: heart failure, coronary artery disease (CAD), hypertension, or no heart disease.
- AAD prescriptions were analyzed for concordance with guideline recommendations based on patient subgroups.
Main Results:
- Only 24% of identified AF patients received qualifying AAD prescriptions.
- Among patients receiving AADs, significant guideline non-adherence was observed: 45% in the heart failure subgroup and 31% in the CAD subgroup.
- AADs inconsistent with first- or second-line recommendations were prevalent in AF patients with heart failure and CAD.
Conclusions:
- Over one-third of AADs prescribed for AF patients with CAD or heart failure deviated from established guidelines.
- Findings indicate a critical need for enhanced clinician education and targeted interventions to ensure safe and guideline-adherent AAD use in AF management.
Background:
Atrial fibrillation (AF) guideline recommendations for antiarrhythmic drugs (AADs) are based on the effectiveness and safety of the AAD in patients with selected, concomitant heart disease. It is unknown to what extent these recommendations are being implemented in clinical practice.
Methods:
Using commercial health claims, patients with AF were identified and then categorized into mutually exclusive, guideline-established subgroups based on their most serious concurrent heart disease: heart failure, coronary artery disease (CAD), hypertension, and no heart disease. Antiarrhythmic drug use after the first AF encounter and the identified concurrent heart disease encounter was determined from prescription claims, and this was compared with guideline recommendations.
Results:
From January 2006 through December 2010, a total of 331,274 patients with AF aged < 65 years were identified: 18%, heart failure; 23%, CAD; 33%, hypertension; and 25%, no heart disease. Of these, 78,877 (24%) patients filled ≥ 1 qualifying AAD prescription. The median age was 57 years (interquartile range 52-61), and 69% were male. A total of 74,191 patients had AADs after both the AF and concurrent heart disease encounters: 27% with heart failure, 25% with CAD, 21% with hypertension, and 19% with no heart disease. In the heart failure and CAD subgroups, 45% and 31% of AADs were inconsistent with first- or second-line guideline recommendations, respectively.
Conclusion:
More than one-third of the AADs used in patients with AF and CAD or heart failure did not conform to guideline recommendations. This highlights the potential need for increased clinician education and intervention to improve the safe use of AADs for AF management.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:25Dysrhythmias VI: Management of Dysrhythmias
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...